natgillin/translations-raw huggingface dataset:
This disorder will persist during the entire life time of the patient and therefore the need for this treatment is lifelong.
To nepravilnost ima bolnik vse življenje, zato je potrebno doživljenjsko zdravljenje.
Do not take Carbaglu if you are hypersensitive (allergic) to carglumic acid or any of the other ingredients of Carbaglu.
Ne jemljite zdravila Carbaglu, če ste preobčutljivi za (alergični na) kargluminsko kislino ali katero koli drugo sestavino zdravila Carbaglu.
Take special care with Carbaglu:
S Carbaglu bodite posebej previdni:
Carbaglu treatment should be initiated under the supervision of a physician experienced in the treatment of metabolic disorders.
Zdravljenje s Carbaglu se sme uvesti le pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem presnovnih bolezni.
Your doctor will test your individual responsiveness to carglumic acid before initiating any long term treatment.
Pred uvedbo dolgotrajnega zdravljenja bo zdravnik preveril, kakšen je vaš individualni odgovor na kargluminsko kislino.
The dose should be adjusted individually in order to maintain normal ammonia plasma levels.
Za vzdrževanje normalne ravni amoniaka v plazmi je treba odmerek individualno prilagajati.
18 Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription
Jemanje drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Taking Carbaglu with food and drink Carbaglu must be taken orally before meals or feedings.
18 Jemanje zdravila Carbaglu s hrano in pijačo Zdravilo Carbaglu morate jemati peroralno pred obrokom hrane ali hranjenjem.
The effects of Carbaglu on pregnancy and the unborn child are not known.
Nosečnost in dojenje Učinki zdravila Carbaglu na nosečnost in na nerojenega otroka niso znani.
Driving and using machines Effects on the ability to drive and use machines are not known.
Vpliv na sposobnost vožnje in upravljanja s stroji ni znan.
Always take Carbaglu exactly as your doctor has instructed you.
Vedno vzemite Carbaglu natančno po navodilih zdravnika.
You should check with your doctor or pharmacist if you are unsure.
Če vam kaj ni jasno, se posvetujte s svojim zdravnikom ali farmacevtom.
- the initial daily dose is usually 100 mg per kilogram of body weight, up to a maximum of
- začetni dnevni odmerek je običajno 100 mg na kilogram telesne mase, do maksimalno 250 mg
250 mg per kilogram of body weight (for example, if you weight 10kg, you should take 1g per day, or 5 tablets),
na kilogram telesne mase (na primer, če tehtate 10 kg, vzemite 1g na dan, kar je 5 tablet),
- in the long term, the daily dose usually ranges from 10 mg to 100 mg per kilogram of body
- ob dolgotrajnem zdravljenju se dnevni odmerek običajno giblje med 10 mg do 100 mg na
weight.
kilogram telesne mase.
When the patient is in hyperammonaemic coma, Carbaglu is administered by fast push through a syringe via the tube set up and used to feed you..
Kadar je bolnik v hiperamonemični komi, se Carbaglu daje z naglim izbrizgom iz brizge skozi vstavljeno cevko, po kateri vas hranijo.
If you take more Carbaglu than you should:
Če uporabite več Carbaglu, kot bi morali:
If you forget to take Carbaglu:
Če pozabite vzeti Carbaglu:
Do not take a double dose to make up for forgotten individual doses.
Ne vzemite dvojnega odmerka, da bi nadomestili izpuščenega.
Like all medicines, Carbaglu can have side effects.
Kot vsa zdravila ima tudi Carbaglu lahko neželene stranske učinke.
The following side effects were reported as follows: very common (occurring in at least one in 10 patients), common (occurring in at least one in 100 patients), uncommon (occurring in at least one
Poročali so o naslednjih neželenih učinkih: zelo pogosti (pojavljajo se pri vsaj enem od 10 bolnikov), pogosti (pojavljajo se pri vsaj enem od 100 bolnikov), občasni (pojavljajo se pri vsaj enem od 1. 000 bolnikov), redki (pojavljajo se pri vsaj enem od 10. 000 bolnikov), zelo redki (pojavljajo se pri vsaj enem od 100. 000 bolnikov). • pogosti: zvečano znojenje • občasni: zvišane transaminaze
If you notice any side effects, please inform your doctor or pharmacist.
Če opazite katerikoli neželeni učinek, vas prosimo, da o tem obvestite svojega zdravnika ali farmacevta.
Do not use after the expiry date stated on the tablet container.
Zdravila X ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na vsebniku s tabletami.
After first opening of the container: do not refrigerate, do not store above 30°C.
Po prvem odprtju vsebnika:
Write the date of opening on the tablet container.
Vsebnik mora biti tesno zaprt zaradi zaščite pred vlago.
- The active substance is carglumic acid.
- Zdravilna učinkovina je kargluminska kislina.
- The other ingredients are microcrystalline cellulose, sodium laurilsulfate, hypromellose,
- Pomožne snovi so mikrokristalna celuloza, natrijev lavrilsulfat, hipromeloza, natrijeva
croscarmellose sodium, silica colloidal anhydrous, sodium stearyl fumarate.
kroskarmeloza, brezvodni koloidni silikagel, natrijev stearilfumarat.
Marketing Authorisation Holder and Manufacturer Orphan Europe Immeuble “ Le Wilson” F-92058 Paris La Défense France Tel: + 33 1 4773 6458 Fax: + 33 1 4900 1800
Imetnik dovoljenja za promet z zdravilom in izdelovalec Orphan Europe Immeuble “ Le Wilson ” F- 92058 Paris La Défense Francija Tel: + 33 1 4773 6458 Fax: + 33 1 4900 1800
20 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
20 Za vse informacije o tem zdravilu se obrnite na lokalnega predstavnika imetnika dovoljenja za promet z zdravilom.
This leaflet was last approved on
{datum}
It is available as capsules (250 mg), tablets (500 mg), a powder to be made up into an oral suspension (1 g/ 5 ml) and a powder to be made up into a solution for infusion (drip into a vein; 500 mg).
Zdravilo je na voljo v obliki kapsul (250 mg), tablet (500 mg), praška za pripravo peroralne suspenzije (1 g/ 5 ml) in praška za pripravo raztopine za infundiranje (kapalna infuzija v veno; 500 mg).
It is used with ciclosporin and corticosteroids (other medicines used to prevent organ rejection).
Uporablja se skupaj s ciklosporinom in kortikosteroidi (druga zdravila za preprečevanje zavrnitve presajenih organov).
CellCept treatment should be initiated and maintained by a qualified transplant specialist.
Zdravljenje z zdravilom CellCept mora vpeljati in voditi specialist za presaditve.
The way that CellCept should be given and the dose depend on the type of organ transplant and the patient ’ s age and size.
Način jemanja zdravila CellCept in odmerek sta odvisna od vrste presajenega organa ter starosti in velikosti bolnika.
For kidney transplants, the recommended dose in adults is 1.0 g twice a day by mouth (capsules, tablets or oral suspension) starting within 72 hours after the transplant.
Pri presaditvi ledvic je priporočeni odmerek za odrasle 1, 0 g dvakrat dnevno peroralno (kapsule, tablete ali peroralna suspenzija), jemanje pa se uvede v 72 urah po presaditvi.
It can also be given as an infusion lasting two hours starting within 24 hours after the transplant, for up to 14 days.
Zdravilo se lahko daje tudi kot infuzija, ki traja dve uri in se začne dajati v 24 urah po presaditvi ter se daje do 14 dni.
In children aged between two and 18 years, the dose of CellCept is calculated depending on height and weight and should be given by mouth.
Pri otrocih, starih od dveh do 18 let, se odmerek zdravila CellCept izračuna glede na višino in maso bolnika, zdravilo pa se jemlje peroralno.
For heart transplants, the recommended adult dose is 1.5 g twice a day by mouth, starting within five days following the transplant.
Pri presaditvi srca je priporočeni odmerek za odrasle 1, 5 g dvakrat dnevno peroralno, zdravilo pa se začne jemati v petih dneh po presaditvi.
For liver transplants in adults, CellCept should be given as a 1-g infusion twice a day for the first four days after the transplant, before the patient is switched to 1.5 g twice a day by mouth as soon as it can be tolerated.
Pri presaditvi jeter pri odraslih je treba prve štiri dni po presaditvi dajati zdravilo CellCept kot 1- gramsko infuzijo dvakrat dnevno, takoj ko je bolnik sposoben požirati, pa se preide na peroralno jemanje 1, 5 g zdravila dvakrat dnevno.
CellCept is not recommended for use in children after heart or liver transplants because of a lack of information on its effects in this group.
Zdravilo CellCept ni priporočeno za otroke po presaditvi srca ali jeter, ker so podatki o učinkih v tej skupini pomanjkljivi.
The active substance in CellCept, mycophenolate mofetil, is an immunosuppressive medicine.
Zdravilna učinkovina zdravila CellCept je mofetilmikofenolat, ki je zdravilo za zmanjšanje imunskega odziva.
This enzyme is important for the formation of DNA in cells, particularly in the 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Zdravilo se v telesu pretvori v mikofenolno kislino, ki zavira encim inozin- monofosfat - 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. lymphocytes (a type of white blood cell which is involved in the rejection of organ transplants).
Ta encim je pomemben za tvorjenje DNA v celicah, še posebej v limfocitih (vrsti belih krvničk, ki sodelujejo pri zavračanju presajenih organov).
By preventing the production of new DNA, CellCept reduces the rate at which the lymphocytes multiply.
Zdravilo CellCept s preprečevanjem tvorjenja nove DNA zmanjša hitrost razmnoževanja limfocitov.
This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected.
Zaradi tega ti niso tako učinkoviti pri prepoznavanju in napadanju presajenih organov, s tem pa se zmanjša tveganje zavrnitve organa.
CellCept was compared with azathioprine (another anti-rejection medicine) in all studies except for one of the kidney transplant studies, in which it was compared with placebo (a dummy treatment).
Zdravilo CellCept so v vseh študijah primerjali z azatioprinom (druga vrsta zdravil proti zavračanju presadkov), razen v eni študiji pri presaditvah ledvic, kjer so ga primerjali s placebom (zdravljenje brez zdravilne učinkovine).
In all of the studies, all of the patients also received ciclosporin and corticosteroids, and the main measure of effectiveness was the proportion of patients whose new organ had been rejected after six months.
V vseh študijah so vsi bolniki prejemali tudi ciklosporin in kortikosteroide, glavno merilo učinkovitosti pa je bil delež bolnikov, pri katerih je telo zavrnilo novi organ po šestih mesecih.
What benefit has CellCept shown during the studies?
Kakšne koristi je zdravilo CellCept izkazalo med raziskavami?
In children undergoing kidney transplants, the rejection rates were similar to those seen in adults taking CellCept and lower than those seen in other studies of children who did not receive CellCept.
Pri otrocih, ki so prestali presaditev ledvic, je bil delež zavrnitev podoben deležu pri odraslih, ki so jemali zdravilo CellCept, in nižji od deleža v drugih študijah pri otrocih, ki niso prejemali zdravila CellCept.
In the heart transplant study, around 38% of patients taking CellCept and those taking azathioprine experienced rejection after six months.
V študiji pri presaditvah srca je po šestih mesecih pri približno 38% bolnikov, ki so jemali zdravilo CellCept in tistih, ki so jemali azatioprin, prišlo do zavrnitve organa.
Following liver transplant, 38% of the patients taking CellCept had rejected their new liver after six months, compared with 48% of those taking azathioprine, but the proportion of patients who had lost their new liver after a year was similar in the two groups, at around 4%.
Po presaditvi jeter je po šestih mesecih pri 38% bolnikov, ki so jemali zdravilo CellCept, prišlo do zavrnitve novih jeter, v primerjavi z 48% tistih, ki so jemali azatioprin, vendar je bil delež bolnikov, pri katerih je prišlo do zavrnitve novih jeter po enem letu, podoben v obeh skupinah, kar je bilo približno 4%.
The most serious risk associated with CellCept is the possible development of cancer, particularly lymphoma and skin cancer.
Najbolj resno tveganje, povezano z zdravilom CellCept, je možnost pojava raka, še posebej limfoma in kožnega raka.
The most common side effects with CellCept used in combination with ciclosporin and corticosteroids (seen in more than 1 patient in 10) are sepsis (blood infection), gastrointestinal candidiasis (a fungal infection of the stomach or gut), urinary tract infection (infection of the structures that carry urine), herpes simplex (a viral infection that causes cold sores), herpes zoster (a viral infection that causes chickenpox and shingles), leucopenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), vomiting, abdominal (tummy) pain, diarrhoea and nausea (feeling sick).
Najpogostejši neželeni učinki, ki so bili opaženi pri uporabi zdravila CellCept v kombinaciji s ciklosporinom in kortikosteroidi (opaženi pri več kot enem bolniku od 10), so sepsa (okužba krvi), gastrointestinalna kandidoza (glivična okužba želodca ali črevesja), okužba urinarnega trakta, herpes simpleks (virusna okužba, ki povzroča značilne kožne mehurčke), herpes zoster (virusna okužba, ki povzroča norice in pasasti izpuščaj), levkopenija (nizko število belih krvničk), trombocitopenija (nizko število trombocitov), anemija (nizko število rdečih krvničk), bruhanje, trebušne bolečine, driska in navzeja (občutek slabosti).
For the full list of side effects reported with CellCept, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila CellCept, glejte Navodilo za uporabo.
CellCept should not be used in people who may be hypersensitive (allergic) to mycophenolate mofetil or mycophenolic acid.
Zdravila CellCept ne smejo uporabljati ljudje, ki so preobčutljivi za (alergični na) mofetilmikofenolat ali mikofenolno kislino.
It should not be used in women are breast-feeding.
Zdravila ne smejo uporabljati ženske, ki dojijo.
CellCept treatment is not recommended for use in pregnant women, and should only be started in women after a negative pregnancy test and if effective contraception is used before, during and for six weeks after CellCept treatment.
Zdravljenje z zdravilom CellCept ni priporočeno za nosečnice, zato lahko ženske začnejo z zdravljenjem šele po negativnem testu nosečnosti ter če pred in med zdravljenjem ter najmanj šest tednov po končani terapiji z zdravilom CellCept uporabljajo učinkovito kontracepcijo.
The Committee for Medicinal Products for Human Use (CHMP) decided that CellCept’ s benefits are greater than its risks in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila CellCept v kombinaciji s ciklosporinom in kortikosteroidi za zaščito pred akutno zavrnitvijo presadkov pri bolnikih, ki prejmejo alogene ledvične, srčne ali jetrne presadke, večje od z njim povezanih tveganj.
The Committee recommended that CellCept be given marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom CellCept.
Other information about CellCept:
Druge informacije o zdravilu CellCept:
The European Commission granted a marketing authorisation valid throughout the European Union for CellCept to Roche Registration Limited on 14 February 1996.
Evropska komisija je dovoljenje za promet z zdravilom CellCept, veljavno po vsej Evropski uniji, odobrila družbi Roche Registration Limited dne 14. februarja 1996.
The marketing authorisation was renewed on 14 February 2001 and on 14 February 2006.
Dovoljenje za promet je bilo podaljšano dne 14. februarja 2001 in 14. februarja 2006.
The full EPAR for CellCept can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo CellCept je na voljo tukaj.
2/ 3 This summary was last updated in 02-2008.
2/ 3 Povzetek je bil nazadnje posodobljen 02- 2008.
Pharmaceutical form
farmacevtska oblika
Route of administration Packaging
pot uporabe
Oral use Blister (PVC/ Alu)
pretisni omot (PVC/ Alu)
Blister (PVC/ Alu)
pretisni omot (PVC/ Alu)
300 capsules
300 kapsul
Each capsule contains 250 mg mycophenolate mofetil.
Vsaka kapsula vsebuje 250 mg mofetilmikofenolata.
CellCept capsules: oblong, blue/ brown, branded with black "CellCept 250" on the capsule cap and "Company logo" on the capsule body.
Trda kapsula CellCept kapsule: ovalne oblike, modro- rjave barve, s črnim napisom “ CellCept 250 ” na glavi kapsule in logom podjetja na telesu kapsule.
Use in renal transplant:
Uporaba pri presaditvi ledvic:
Adults: oral CellCept should be initiated within 72 hours following transplantation.
Odrasli: peroralno dajanje zdravila CellCept je treba uvesti v 72 urah po presaditvi.
Children and adolescents (aged 2 to 18 years): the recommended dose of mycophenolate mofetil is 600 mg/ m2 administered orally twice daily (up to a maximum of 2 g daily).
Otroci in mladostniki (stari od 2 do 18 let): priporočeni odmerek mofetilmikofenolata je 600 mg/ m2, peroralno dvakrat na dan (do največ 2 g na dan).
CellCept capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.
Kapsule CellCept lahko predpišemo samo bolnikom, katerih telesna površina je najmanj 1, 25 m2.
Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed CellCept capsules at a dose of 750 mg twice daily (1.5 g daily dose).
Bolnikom s telesno površino med 1, 25 in 1, 5 m2 predpišemo kapsule CellCept v odmerku 750 mg dvakrat na dan (dnevni odmerek 1, 5 g).
Patients with a body surface area greater than 1.5 m2 may be prescribed CellCept capsules at a dose of 1 g twice daily (2 g daily dose).
Bolnikom s telesno površino nad 1, 5 m2 predpišemo kapsule CellCept v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction.
Pri tem je treba upoštevati ustrezne klinične dejavnike vključno z resnostjo neželenega učinka.
Children (< 2 years): there are limited safety and efficacy data in children below the age of 2 years.
Otroci, mlajši od 2 let: o varnosti in učinkovitosti pri otrocih, mlajših od dveh let, je na voljo premalo podatkov.
Use in cardiac transplant:
Uporaba pri presaditvi srca:
Adults: oral CellCept should be initiated within 5 days following transplantation.
Odrasli: peroralno dajanje zdravila CellCept je treba uvesti v 5 dneh po presaditvi.
The recommended dose in cardiac transplant patients is 1.5 g administered twice daily (3 g daily dose).
Priporočeni odmerek pri bolnikih s srčnim presadkom je 1, 5 g dvakrat na dan (dnevni odmerek 3 g).
Children: no data are available for paediatric cardiac transplant patients.
Otroci: za otroke s srčnim presadkom podatkov ni.
2 Use in hepatic transplant:
Uporaba pri presaditvi jeter:
IV CellCept should be administered for the first 4 days following hepatic transplant, with oral CellCept initiated as soon after this as it can be tolerated.
2 Odrasli: prve 4 dni po presaditvi jeter je treba dajati zdravilo CellCept intravensko, takoj ko je bolnik sposoben požirati, pa nadaljujemo s peroralno obliko zdravila CellCept.
The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose).
Priporočeni peroralni odmerek pri bolnikih z jetrnim presadkom je 1, 5 g dvakrat na dan (dnevni odmerek 3 g).
Children: no data are available for paediatric hepatic transplant patients.
Otroci: za otroke in mladostnike z jetrnim presadkom podatkov ni.
Use in elderly (≥ 65 years): the recommended dose of 1 g administered twice a day for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly.
Uporaba pri starejših bolnikih (stari 65 let ali več): priporočeni odmerek za starejše bolnike je 1 g dvakrat na dan za bolnike z ledvičnim presadkom in 1, 5 g dvakrat na dan za bolnike s srčnim ali jetrnim presadkom.
Use in renal impairment: in renal transplant patients with severe chronic renal impairment (glomerular filtration rate < 25 ml• min-1• 1.73 m-2), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided.
Uporaba pri bolnikih z ledvično okvaro: bolnikom s hudo kronično ledvično okvaro (glomerulna filtracija < 25 ml• min- 1 • 1, 73 m- 2) izven obdobja neposredno po presaditvi ne dajemo odmerkov, večjih od 1 g dvakrat na dan.
No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively (see section 5.2).
Bolnikom, pri katerih se je po operaciji primerno ledvično delovanje presadka vzpostavilo z zakasnitvijo, prilagajanje odmerkov ni potrebno (glejte poglavje 5. 2).
Use in severe hepatic impairment: no dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Uporaba pri bolnikih z jetrno okvaro: bolnikom z ledvičnim presadkom in hudo boleznijo jetrnega parenhima ni treba prilagajati odmerkov.
MPA (mycophenolic acid) is the active metabolite of mycophenolate mofetil.
Zdravljenje med zavrnitveno reakcijo: aktivni presnovek mofetilmikofenolata je mikofenolna kislina (MFK).
Therefore, CellCept is contraindicated in patients with a hypersensitivity to mycophenolate mofetil or mycophenolic acid.
Opazili so preobčutljivostne reakcije na zdravilo CellCept (glejte poglavje 4. 8), zato je kontraindiciran pri bolnikih s preobčutljivostjo za mofetilmikofenolat ali mikofenolno kislino.
CellCept is contraindicated in women who are breastfeeding (see section 4.6).
Zdravilo CellCept je kontraindicirano pri ženskah, ki dojijo (glejte poglavje 4. 6).
For information on use in pregnancy and contraceptive requirements see section 4.6.
Za informacijo o uporabi med nosečnostjo in zahtevah glede kontracepcije glejte poglavje 4. 6.
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
Bolniki, ki prejemajo kombinacije imunosupresivnih zdravil, vključno z zdravilom CellCept, so izpostavljeni povečanem tveganju nastanka limfomov in drugih malignih sprememb, zlasti kožnih (glejte poglavje 4. 8).
As general advice to minimise the risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.
Splošen nasvet za zmanjšanje tveganja nastanka kožnega raka je, da se bolniki ne izpostavljajo soncu in UV- svetlobi brez uporabe zaščitne obleke in sončne kreme z visokim zaščitnim faktorjem.
Patients receiving CellCept should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.
Bolnikom, ki prejemajo zdravilo CellCept, je treba naročiti, da morajo takoj poročati o kakršnemkoli znaku okužbe, nepričakovani modrici, krvavitvi ali drugih znakih depresije kostnega mozga.
Patients treated with immunosuppressants, including CellCept, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8).
Bolniki, ki se zdravijo z imunosupresivi, vključno z zdravilom CellCept, imajo povečano tveganje za oportunistične okužbe (bakterijske, glivične, virusne in protozojske), smrtne okužbe in sepso (glejte poglavje 4. 8).
Among the opportunistic infections are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
Oportunistične okužbe vključujejo nefropatijo, povezano z virusom BK in progresivno multifokalno levkoencefalopatijo (PML), povezano z virusom JC.